|
| 质量项目 |
在试验报告质量项目
N (%) |
项目和出版质量年度报告之间的联系
或每年1979后(95% CI), p |
报告质量项目之间的联系,积极试验的可能性
或(95% CI), p
|
|
| 偏见的风险 |
|
|
|
| 分配隐藏 |
68 (35.1) |
1.06 (1.00,1.14),0.09 |
2.04 (0.67,6.16),0.21 |
| 序列生成 |
58 (29.9)__ |
1.0 (0.85,1.17),0.99 |
3.27 (0.27,40.2),0.35 |
| 检测偏差处理 |
‡90 (46.4) |
1.02 (0.96,1.08),0.55 |
0.83 (0.36,1.91),0.67 |
| 干预剂量 |
|
|
|
| 剂量进度报告 |
148 (76.3) |
1.06 (1.01,1.10),0.01 |
1.52 (0.76,3.09),0.24 |
| 剂量强度报告 |
69 (35.6) |
1.06 (1.01,1.12),0.02 |
0.49 (0.26,0.92),0.03 |
| 合理的剂量 |
36 (18.6) |
1.01 (0.95,1.06),0.89 |
0.59 (0.28,1.26),0.17 |
| 试验设计 |
|
|
|
| 假设说 |
71 (36.6) |
1.09 (1.03,1.15),0.002 |
1.33 (0.73,2.46),0.36 |
| 主要结果表示 |
49 (25.3) |
1.16 (1.08,1.26),< 0.001 |
1.22 (0.61,2.45),0.56 |
| 审判阶段表示 |
15 (7.7) |
1.09 (0.98,1.20),0.12 |
0.70 (0.40,1.24),0.22 |
| 登记试验 |
10 (5.2) |
3.32 (1.58,6.95),0.001 |
0.61 (0.37,5.49),0.61 |
| 使用委员会 |
1 (0.5) |
1.33 (0.68,2.63),0.41 |
N / A§ |
| 研究地点指定 |
124 (63.9) |
1.01 (0.96,1.05),0.87 |
0.99 (0.53,1.84),0.97 |
| 生物原理的干预 |
60 (30.9) |
1.11 (1.04,1.17),0.001 |
2.18 (1.14,4.19),0.02 |
| 遵守干预报道 |
69 (35.6) |
1.05 (1.01 - 1.10),0.048 |
1.33 (0.71,2.49),0.37 |
| 实际干预收到报告 |
22日(11.3) |
1.14 (1.03,1.27),0.02 |
1.48 (0.57,3.84),0.42 |
| 不良事件报告 |
22日(11.3) |
1.09 (1.01,1.19),0.07 |
1.42 (0.56,3.62),0.46 |
|
|
